Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's disease

• Published in: Alzheimer's & dementia : translational research & clinical interventions Vol. 9; no. 3; pp. e12415 - n/a
• Main Authors: Shcherbinin, Sergey, Morris, Amanda, Higgins, Ixavier A., Tunali, Ilke, Lu, Ming, Deveau, Carmen, Southekal, Sudeepti, Kotari, Vikas, Evans, Cynthia D., Arora, Anupa K., Collins, Emily C., Pontecorvo, Michael, Mintun, Mark A., Sims, John R.
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.07.2023; John Wiley and Sons Inc; Wiley
• Subjects: Alzheimer's disease; amyloid; Biomarkers; Brain research; Cognitive ability; correlation; Dementia; diagnosis; FDA approval; imaging; International organizations; Medical diagnosis; Pathology; prediction; Tomography; amyloid; correlation; prediction; diagnosis; tau; Alzheimer's disease; imaging

Alzheimer's disease (AD) is characterized by the presence of both amyloid and tau pathology. In vivo diagnosis can be made with amyloid and tau positron emission tomography (PET) imaging. Emergent evidence supports that amyloid and tau accumulation are associated and that amyloid accumulation m...